

RESEARCH

Open Access

Plasma levels of mitochondrial and nuclear DNA in patients with massive pulmonary embolism in the emergency department: a prospective cohort study

Francisco Arnalich^{1*}, Maria Constanza Maldifassi², Enrique Ciria¹, Rosa Codoceo³, Jaime Renart⁴, Carmen Fernández-Capitán¹, Rafael Herruzo⁵, Francisco Garcia-Rio⁶, Eduardo López-Collazo⁶ and Carmen Montiel²

Abstract

Introduction: Cell-free plasma mitochondrial DNA (mt-DNA) and nuclear DNA (n-DNA) are biomarkers with prognostic utility in conditions associated with a high rate of cell death. This exploratory study aimed to determine the plasma levels of both nucleic acids in patients with massive and submassive pulmonary embolism (PE) and to compare them with other biomarkers, such as heart-type fatty acid-binding protein (H-FABP) and troponin I (Tn-I)

Methods: This was a prospective observational study of 37 consecutive patients with massive PE, 37 patients with submassive PE, and 37 healthy subjects. Quantifications of plasma mt-DNA and n-DNA with real-time quantitative polymerase chain reaction (PCR), and plasma H-FABP and Tn-I by commercial assays, were done on blood samples drawn within 4 hours after presentation at the emergency department.

Results: Plasma mt-DNA and n-DNA concentrations were much higher in patients with massive PE (median, 2,970 GE/ml; interquartile range (IQR), 1,050 to 5,485; and 3,325 GE/ml, IQR: 1,080 to 5,790, respectively) than in patients with submassive PE (870 GE/ml and 1,245 GE/ml, respectively; $P < 0.01$) or controls (185 GE/ml and 520 GE/ml, respectively). Eighteen patients with massive PE died of a PE-related cause by day 15 of observation. Plasma mt-DNA and n-DNA values were 2.3-fold and 1.9-fold higher in the subgroup of nonsurviving patients than in survivors. H-FABP and Tn-I values were also higher in patients with massive PE who died (7.3 ng/ml and 0.023 ng/ml, respectively) than in those who survived (6.4 ng/ml, and 0.016 ng/ml, respectively). By receiver operating curve (ROC) analysis, the best cutoff values for predicting 15-day mortality were 3,380 GE/ml for mt-DNA, 6.8 ng/ml for H-FABP, 3,625 GE/ml for n-DNA, and 0.020 ng/ml for Tn-I, based on the calculated areas under the curve (AUCs) of 0.89 (95% confidence interval (CI), 0.78 to 0.99), 0.76 (95% CI, 0.69 to 0.93), 0.73 (95% CI, 0.58 to 0.91), and 0.59 (95% CI, 0.41 to 0.79), respectively. By stepwise logistic regression, a plasma mt-DNA concentration greater than 3,380 GE/ml (adjusted odds ratio (OR), 8.22; 95% CI, 1.72 to 39.18; $P < 0.001$) and a plasma value of H-FABP > 6.8 ng/ml (OR, 5.36; 95% CI, 1.06 to 27.08; $P < 0.01$) were the only independent predictors of mortality.

Conclusions: mt-DNA and H-FABP might be promising markers for predicting 15-day mortality in massive PE, with mt-DNA having better prognostic accuracy.

Keywords: plasma mitochondrial DNA, plasma nuclear DNA, cell-free plasma DNA, heart-type fatty acid-binding protein, hospital mortality, massive pulmonary embolism, prognosis

* Correspondence: farnalich.hulp@salud.madrid.org

¹Department of Internal Medicine and Emergency Medicine Service, Hospital Universitario La Paz. IdiPAZ. Paseo de la Castellana 261.28046 Madrid, Spain
Full list of author information is available at the end of the article

Introduction

Massive pulmonary embolism (PE) is an infrequent cardiovascular emergency that carries a very high mortality rate [1,2]. Assessment of right ventricular (RV) function and measurement of cardiac biomarkers (troponins, brain natriuretic peptide (BNP), or heart-type fatty acid-binding protein (H-FABP)) released to serum from the RV, accurately predict 30-day mortality in patients with submassive PE [3-7]. Unfortunately, no data are yet available to support the usefulness of cardiac biomarkers in predicting mortality in patients with massive PE [4].

Cell-free plasma DNA comprises small DNA fragments derived from nuclear or mitochondrial double-stranded molecules that are found at very low concentrations circulating in peripheral blood from healthy people. Both nuclear DNA (n-DNA) and mitochondrial DNA (mt-DNA) are released into the circulation from apoptotic and necrotic cells, although the exact mechanism is unclear [8,9]. Cell-free plasma n-DNA and mt-DNA are biomarkers with prognostic utility in a range of conditions associated with a high rate of cell death, including trauma [10], stroke [11], myocardial infarction [12], burns [13], sepsis, and critical conditions [14-16]. We and others reported that high concentrations of plasma n-DNA can predict treatment outcomes and mortality in conditions associated with global ischemia-reperfusion injury, such as acute mesenteric ischemia and cardiac arrest [17-19]. High plasma concentrations of both mt-DNA and n-DNA have been found in patients with acute ischemic stroke, bacterial meningitis, and sepsis [20-22], and with similar prognostic values. In contrast, recent data indicate that increased mt-DNA concentration is a more powerful prognostic marker than plasma n-DNA in patients with out-of-hospital cardiac arrest [23].

Detection of plasma DNA with counterimmunoelectrophoresis was proposed as a screening test for the diagnosis of PE [24]. One study conducted two decades ago showed that increased plasma DNA concentrations had a sensitivity of 82% and a specificity of 85% in detecting patients with PE [25], but no subsequent study evaluated the potential prognostic value in patients with high-risk PE. Examining this question is relevant because those patients have widespread tissue hypoxia that decreases oxygen availability for mitochondria, leading to a rapid depletion of ATP synthesis and cell death via the intrinsic pathway of apoptosis [26]. We hypothesized that the amount of plasma mt-DNA, released to the circulation from apoptotic cells, could be a good new marker of cell damage caused by acute RV myocardial ischemia in patients with massive PE.

This exploratory study aimed to determine the plasma levels of both nucleic acids in patients with massive and submassive PE presenting at the emergency department

(ED) and to compare them with other biomarkers, such as heart-type fatty acid-binding protein (H-FABP) and troponin I (Tn-I).

Materials and methods

Patients and setting

We performed a prospective observational study of 74 consecutive patients admitted to the ED with acute massive or submassive PE, confirmed with computed tomographic pulmonary angiography (CTPA), who were classified into two groups: 37 patients with massive PE and 37 patients with submassive PE, based on their systolic blood pressure on admission and the presence of echocardiographic findings of right ventricular (RV) dysfunction. The study was conducted from January 2005 through May 2007 at La Paz University Hospital in Madrid, Spain, an academic tertiary care hospital with annual ED visits of around 120,000. Massive PE was diagnosed in patients who met the following criteria: (a) systolic blood pressure <90 mm Hg or a pressure decrease of ≥ 40 mm Hg for >15 minutes at arriving in the ED, requiring catecholamine administration to maintain adequate organ perfusion, if not due to new-onset arrhythmia, hypovolemia, sepsis, acute coronary syndrome, or acute left ventricular failure; (b) partial oxygen arterial pressure ≤ 80 mm Hg while receiving supplemental oxygen of 2 L/min, in the absence of pulmonary infiltrates on chest radiograph film.

Submassive PE was diagnosed in patients who were normotensive on admission and had echocardiographic signs of RV dysfunction (see Additional file 1, methods). Exclusion criteria were (a) end-stage heart or renal failure, (b) clinical conditions that might be associated with increased plasma DNA concentrations (metastatic cancer, multiple trauma, stroke, severe sepsis or septic shock, acute myocardial infarction, cardiac arrest). Sample size of the massive-PE group was estimated based on our previous studies in patients with out-of-hospital cardiac arrest, showing that plasma DNA concentrations were at least 1.5-fold higher in patients who died than in survivors [18,23]. Assuming a mortality rate between 30% and 50% in patients with massive PE, and that the magnitude of differences in plasma nucleic acids between survivors and nonsurvivors would be similar in massive PE, we estimated that a sample size of 37 patients would be sufficient to keep a type I (α) error of 0.05 and a type II (β) error of 0.20. The submassive-PE group consisted of the same number of patients, matched in age and gender to the massive-PE group. Each patient's baseline characteristic determined their risk classification, according to the predictive pulmonary severity index (PESI) model [27]. Thirty-seven healthy community subjects or relatives of patients taking no medications, with a normal physical

and analytic check-up, were recruited as the control group. The study protocol was approved by the local research ethics committee. All study and controls subjects or their legal designees signed a written informed consent.

The end point of the study was 15-day PE-related death. Cause of death was judged to be definitive fatal PE, if it was confirmed by autopsy. Possible fatal PE was considered in a patient who died suddenly or unexpectedly of severe PE in the absence of any alternative cause. All patients received standard anticoagulation therapy with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin. Thrombolytic therapy was strongly considered in patients with massive PE. However, mainly because of high-risk bleeding (six cases) or of the patient legal designee's refusal to allow thrombolysis (nine cases), only 20 patients were actually given thrombolysis (2-hour infusion of 100 mg recombinant tissue plasminogen activator).

Blood sampling, processing of plasma, and DNA extraction

A 10-ml blood sample was taken within approximately 4 hours (range, 1 to 7 hours) from admission to the ED, either before heparin administration or less than 2 hours after heparin administration, during the diagnostic workup. After confirmation of the diagnosis, patients or their relatives were asked to authorize the use of thrombolytic therapy and to sign the informed consent form for enrollment into the study. Therefore, in all the cases, blood was obtained before thrombolysis. We prepared and measured plasma DNA by the same methods we used previously [17,18,23]. Plasma and cells were separated by centrifugation at 1,800 g (+4°C) for 10 minutes, and plasma samples were stored at -80°C. Afterward, plasma was carefully removed from tubes without shaking the buffy coat, transferred to plain polypropylene tubes, and centrifuged at 16,000 g (+4°C) for 10 minutes. The supernatants were collected into fresh polypropylene tubes and stored at -80°C until further processing. Cell-free DNA was extracted from 200-μl plasma samples by using the QIAamp DNA Blood Mini Kit (Qiagen, Hidden, Germany), according to the manufacturer's recommendations.

Real-time quantitative PCR

Cell-free plasma DNA copy numbers were measured with real-time quantitative PCR assay (Roche Lightcycler; Roche, Lewes, UK) by using specific primers to amplify the *β-globin* and *MT-ND2* genes [28,29]. Although the first gene is present in all nucleated cells of the body, the second is unique to mitochondria. An SYBR green-based assay for amplicon detection on the ABI Prism 7900 device was used, as previously described [28]. The following primers were designed for the

β-globin gene (GenBank accession number U01317): 354-forward (5'-GTGCACCTGACTCCTGAGGAGA-3') and 455-reverse (5'-CCTTGATACCAACCTGCCCAG-3'), and for the *MT-ND2* gene (GenBank accession number NC012920): 156-forward (5'-CACAGA AGCTGC-CAT CAAGTA-3') and 245-reverse (5'-CCGGAGAGTAT ATTGTTGAAGAG-3'). Two amplicons of 101-bp (n-DNA) and 90-bp (mt-DNA) were obtained, respectively, in each of these PCR reactions. A 10-fold serial dilution of human genomic DNA (Roche) was used to construct the calibration curve, which was included in each PCR reaction. The imprecision of this experimental approach was previously reported [28,29], with an interassay CV of the threshold cycle (Ct) values ranging from 0.5% to 1.1%. Results are expressed as genome equivalents (GE)/ml plasma (1 GE = 6.6 pg DNA), with a detection limit of 12.5 GE/ml.

Laboratory measurements

The plasma levels of different biomarkers were measured as follows: (a) D-dimer by immunoturbidimetric assay (INNOVANCE D-Dimer assay; Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany); (b) Tn-I and NT-proBNP with quantitative electrochemiluminescence immunoassays (Dimension Vista System analyzer; Siemens Healthcare Diagnostics, DE, USA); (c) H-FABP (dilution 1:5) by a solid-phase enzyme-linked immunoadsorbent assay (HyCult Biotechnology, Uden, The Netherlands); (d) markers involved in Fas-related apoptosis, human soluble Fas (sFas), and soluble Fas ligand (sFasL) molecules, with enzyme immunoassay (Quantikine; R&D Systems, Minneapolis, MN, USA) [see Additional file 1, methods]. All other laboratory analyses were performed with standard techniques. Renal insufficiency was defined as a glomerular filtration rate <60 ml/min/1.73 m². The glomerular filtration rate was calculated by using the abbreviated Modification of Diet in Renal Disease formula [31].

Statistical analysis

Continuous variables are expressed as medians and interquartile ranges (IQR, 25th to 75th percentiles) and compared with the Mann-Whitney *U* test. Categorical variables were given as absolute values and percentages and compared with χ^2 , by using the Fisher exact test when appropriate. We determined bivariate relations by using nonparametric Spearman rank correlation. Receiver operating characteristic (ROC) curves were constructed to determine the optimal cutoff values for maximal sensitivity and specificity of different laboratory markers for predicting the primary end point of 30-day mortality. Comparison of AUCs was performed as recommended by DeLong et al. [32]. The results are presented as odds ratio (ORs) with the corresponding 95% CIs. Kaplan-Meier analysis was performed for cumulative survival, and log-rank

values were used to assess statistical significance. All significant variables were then tested in a multivariable logistic regression analysis model by using forward variable selection to identify factors that had independent predictive value for 15-day mortality. Statistical significance was set at $P < 0.05$ in all tests. All statistical analyses were performed by using the SPSS for Windows 15.0 (SPSS Inc, Chicago, IL, USA) and MedCalc 9.6.4.0 (MedCalc Software).

Results

Eighteen (48.6%) patients with massive PE died by day 15 of observation, five of them during the first 48 hours. Ten (58.8%) deaths occurred in the group of 17 patients who did not receive thrombolysis, and eight (40.0%) deaths among the 20 patients after thrombolysis. Three patients died of PE confirmed at autopsy. Thirteen PE-related deaths were caused by irreversible RV dysfunction in the absence of any alternative diagnosis. In four other patients, a major hemorrhage probably contributed to death. The median duration of the ICU stay was 14 days (IQR, 5 to 20), and the median time until hospital discharge for survivors was 32 days (IQR, 20 to 51). By contrast, in the submassive-PE group, no deaths occurred, and only five patients required ICU admission (median stay, 4 days). As shown in Table 1, demographics and predisposing risk factors were not significantly different between patients with massive and submassive PE or between patients with massive PE who died and those who survived. Patients' symptoms and physical findings at presentation were similar in survivors and nonsurvivors. The proportion of patients with PESI (pulmonary embolism severity index) risk classes V and the presence of obstructive shock were significantly higher in nonsurvivors than in survivors. Table 2 displays baseline plasma concentrations of cardiac markers, soluble apoptosis-signaling molecules, mt-DNA, and n-DNA in the three study subjects groups. Statistically significant differences were observed among these variables when all groups were compared (Kruskal-Wallis test; $P < 0.01$). Significantly higher values of all parameters were observed in submassive and massive PE compared with controls, as well as in the submassive-PE group compared with massive-PE group (Mann-Whitney U test, corrected by Bonferroni; $P < 0.01$). With regard to the massive-PE group, the median cell-free plasma mt-DNA and n-DNA concentrations at admission were higher in nonsurvivors (4,220 GE/ml and 4,450 GE/ml, respectively) than in survivors (1,830 GE/ml and 2,285 GE/ml, respectively; $P < 0.01$). Significantly higher plasma H-FABP and Tn-I levels, but not significant differences in NT-proBNP concentrations, were noted in patients who died compared with survivors. A significant increase in sFas levels was found in nonsurvivors. The baseline characteristics of massive-PE patients who did and did not receive thrombolysis were

similar, except for the fact that thrombolysis patients had significantly higher acidosis and hyperlactatemia. No significant differences were found in plasma concentrations of cardiac markers, apoptosis-signaling molecules, or nucleic acids between both patient subgroups (see Additional file 2, Table S1). Total point scores of PESI were not significantly associated with plasma concentrations of any of these markers. Significant correlations were found between plasma mt-DNA and n-DNA concentrations ($r = 0.568$; $P < 0.01$), and between each of them and H-FABP values ($r = 0.476$ and $r = 0.412$, respectively; $P < 0.01$). Plasma mt-DNA levels also correlated with lactate concentrations ($r = 0.451$; $P < 0.01$) and with sFas value ($r = 0.379$; $P < 0.01$). In contrast, no significant correlation was noted between plasma n-DNA and lactate ($r = 0.180$; $P = 0.115$) or sFas values ($r = 0.077$; $P = 0.624$). Neither mt-DNA nor n-DNA concentrations correlated significantly with creatinine clearance.

ROC curves were calculated for the use of plasma of mt-DNA and n-DNA and two specific cardiac markers, H-FBAP and Tn-I, to predict 15-day mortality (Figures 1 and 2). The best cut-offs were 3,380 GE/ml for mt-DNA, 6.8 ng/ml for H-FABP, 3,625 GE/ml for n-DNA, and 0.020 ng/ml for Tn-I, based on the calculated AUCs of 0.89 (95% CI, 0.78 to 0.99), 0.76 (95% CI, 0.69 to 0.93), 0.73 (95% CI, 0.58 to 0.91), and 0.59 (95% CI, 0.41 to 0.79), respectively (Table 3). The AUC for mt-DNA was similar to that for H-FBAP ($P = 0.082$) but significantly higher than the AUC for n-DNA ($P = 0.026$), and higher than the AUC for Tn-I ($P = 0.015$), in a comparison of all four AUCs, according to DeLong's method [32]. The discriminant power of these cut-off values (sensitivity, specificity, positive and negative predictive value (PNV, NPV), and likelihood ratio for positive (+LR) and negative (-LR)) are shown in Table 3. Kaplan-Meier survival curves using the best cutoff values of mt-DNA, H-FBAP, and n-DNA are presented in Figure 3 (A through C).

We performed multiple logistic regression analysis to identify factors having independent predictive value for mortality. All parameters significantly associated with hospital mortality by univariable analysis (the presence of shock as the only categorical variable, and the serum or plasma concentrations of analytic variables) were included in a multivariable analysis. A plasma mt-DNA concentration $>3,380$ GE/ml (adjusted OR, 8.22; 95% CI, 1.72 to 39.18; $P < 0.001$) and a plasma value of H-FBAP >6.8 ng/ml (OR, 5.36; 95% CI, 1.06 to 27.08; $P < 0.01$) were the only independent predictors of mortality.

Discussion

Earlier studies showed detectable plasma DNA in patients with PE, but DNA was measured by using a counter-immunoelectrophoresis technique that yielded unsatisfactory results [24,25]. This is the first prospective

Table 1 Descriptive characteristic of the study groups

	Submassive <i>P.Embolism</i> (<i>n</i> = 37)	Total (<i>n</i> = 37)	Massive Pulmonary Embolism		P value A	P value B	Healthy controls (<i>n</i> = 37)	
			Survivors (<i>n</i> = 19)	Non-survivors (<i>n</i> = 18)				
Demographics	Age	67 (58-73)	68 (59-74)	66 (59-72)	70 (60-74)	NS	NS	65 (58-74)
	Female	26 (70.2)	26 (70.2)	12 (63.1)	14 (77.7)	NS	NS	24 868.6)
Risk factors	Obesity (BMI >30)	12 (32.4)	14 (37.8)	6 (31.5)	8 (44.4)	NS	NS	
	Immobilization (bed rest)	6 (16.2)	8 (21.6)	3 (15.8)	5 (27.7)	NS	NS	
	Recent major surgery (< 30 d)	6 (16.2)	9 (24.3)	4 (21.1)	5 (27.7)	NS	NS	
	Chronic heart failure	10 (27.0)	12 (32.4)	5 (26.3)	7 (38.9)	NS	NS	
	COPD/emphysema	7 (18.9)	8 (21.6)	4 (21.1)	4 (22.2)	NS	NS	
	Cancer (inactive)	3 (8.1)	5 (13.5)	2 (10.5)	3 (16.6)	NS	NS	
	Previous DVT	6 (16.2)	7 (18.9)	4 (21.1)	3 (16.6)	NS	NS	
	Concurrent DVT	10 (27.0)	14 (37.8)	6 (31.5)	8 (44.4)	NS	NS	
	Unknown	14 (37.8)	13 (35.1)	7 (36.8)	6 (33.3)	NS	NS	
Clinical data	Acute onset of dyspnea	21 (56.7)	31 (83.8)	16 (84.2)	15 (83.3)	<0.01	NS	
	Acute chest pain	9 (24.3)	13 (35.1)	6 (31.5)	7 (38.9)	NS	NS	
	Preceding syncope	3 (8.1)	15 (40.5)	7 (36.8)	8 (44.4)	<0.01	NS	
	Systolic blood pressure, mm Hg	119 (113-128)	74 (68-83)	75 (69-82)	73 (67-83)	<0.01	NS	125 (118-134)
	Mean blood pressure, mm Hg	83 (77-91)	46 (38-54)	45 (39-54)	44 (38-52)	<0.01	NS	86 (78-95)
	PaO ₂ mm Hg	93 (90-97)	67 (64-72)	68 (64-73)	66 (63-72)	<0.01	NS	95 (91-98)
	PESI risk class III	11 (29.7)	0 (0.0)	0 (0.0)	0 (0.0)	<0.01	NS	
	PESI risk class IV	20 (70.3)	16 (43.2)	9 (56.2)	7 (43.8)	<0.01	NS	
	PESI risk class V	6 (16.2)	21 (56.8)	8 (38.1)	13 (61.9)	<0.01	<0.05	
Specific treatment	Thrombolysis (within 24 h)	0	20 (54.5)	11 (57.9)	9 (50.0)	—	NS	
	Caval filter implantation	0	2 (4.4)	1 (5.3)	1 (5.5)	—	NS	
Complications/outcome	Obstructive shock (within 24 h)	2 (5.4)	18 (48.6)	6 (31.6)	12 (66.6)	<0.01	<0.01	
	Mechanical ventilation	0	10 (27.0)	4 (21.1)	6 (33.3)	<0.01	NS	
	Major bleeding	0	4 (10.8)	2 (10.5)	2 (11.1)	—	NS	
Laboratory values	pH	7.35 (7.32-7.38)	7.23 (7.19-7.27)	7.25 (7.18-7.31)	7.20 (7.16-7.27)	<0.01	<0.05	7.38 (7.35-7.40)
	Basal lactate (mmol/l)	2.2 (1.6-2.7)	5.7 (4.5-7.3)	4.9 (4.5-6.1)	6.4 (5.7-7.3)	<0.01	<0.05	1.8 (1.3-2.1)
	Estimated GFR (ml/min/1.73 m ²)	69 (65-73)	65 (61-73)	67 (63-73)	63 (61-67)	<0.01	NS	71 (66-75)


Data are median (IQR) or number (%); A: comparison of massive vs. submassive group.; B: comparison of survivors vs. non-survivors.

Table 2 Comparison of factors associated with 15-day mortality.


	Healthy controls (n = 37)	Submassive PE (n = 37)	Massive PE (n = 37)	Mann-Whitney U-test (Massive vs Submassive PE)	Massive PE Survivors (n = 19)	Massive PE Non-survivors (n = 18)	Mann-Whitney U-test (Non-survivors vs Survivors)
Troponin I (ng/ml)	0.003 (0.001-0.005)	0.009 (0.006-0.012)	0.019 (0.012-0.028)	-3.040 <i>p</i> <0.002	0.016 (0.012-0.023)	0.023 (0.014-0.28)	-2.042 <i>p</i> <0.04
D- dimer (µg/ml)	0.5 (0.1-0.8)	7.8 (4.1-10.4)	12.6 (8.2-15.8)	-2.309 <i>p</i> <0.021	11.9 (8.2-15.3)	13.7 (10.6-15.8)	-1.004 NS
NT-proBNP (pg/ml)	235 (130-350)	570 355-840	1720 (770-3185)	-2.750 <i>p</i> <0.006	1510 (770-2140)	1940 (950-3185)	-1.332 NS
H-FBAP (ng/ml)	1.4 (0.8-2.1)	3.1 (1.6-4.2)	6.8 (5.7-7.8)	-3.520 <i>p</i> <0.001	6.4 (5.7-7.4)	7.3 (6.1-7.8)	-2.839 <i>p</i> <0.05
Plasma n- DNA (GE/ml)	520 (230-760)	1245 (680-2315)	3325 (1080-5790)	-3.039 <i>p</i> <0.002	2285 (1280-4010)	4450 (1130-5780)	-2.750 <i>p</i> <0.016
Plasma mt- DNA (GE/ml)	185 (70-430)	870 (365-1690)	2970 (1050-5485)	-4.151 <i>p</i> <0.000	1830 (1050-3215)	4220 (2110-5510)	-3.769 <i>p</i> <0.001
Plasma sFas (pg/ml)	1070 (530-1650)	3355 (640-6720)	8940 (5330-13270)	-2.408 <i>p</i> <0.013	7680 (6330-9400)	10570 (9050-12870)	-2.355 <i>p</i> <0.019
Plasma sFasL (pg/ml)	460 (355-540)	510 (285-580)	790 (570-920)	-1.265 NS	755 (570-845)	810 (640-920)	-1.265 NS

Data are median (IQR);

COPD: chronic obstructive pulmonary disease; DVP: deep venous thrombosis; pro-BNP: pro-Brain Natriuretic Peptide; H-FBAP: heart-type fatty acid-binding protein; sFas: soluble Fas molecule; sFasL: soluble Fas ligand molecule.



observational study to evaluate cell-free plasma mt-DNA and n-DNA concentrations by real-time specific PCR in patients with massive and submassive PE presenting at the ED and to compare them with two specific cardiac markers, H-FABP and Tn-I. We found that plasma



concentrations of mt-DNA and n-DNA, H-FABP, and Tn-I were significantly higher in patients with massive PE than in patients with submassive PE. Significantly higher values of these biochemical markers were observed in nonsurviving patients with massive PE than in those who survived. For the prediction of hospital mortality, plasma mt-DNA showed a better discriminative power than that of the other biochemical markers. Furthermore, by multivariable logistic regression analysis, plasma mt-DNA and H-FABP values >3,380 GE/ml and 6.8 ng/ml, respectively, were independent predictors of mortality. However, plasma n-DNA was not an independent predictor and showed less prognostic accuracy.

This report adds new information to existing literature for the study of cell-free plasma circulating nucleic acids in critically ill patients [10-17]. Recently, we and others found elevated plasma levels of cell-free n-DNA in cardiac-arrest patients during the early postresuscitation phase [18,19], a period when reperfusion after whole-body ischemia may trigger a systemic inflammatory response similar to that seen in severe sepsis, causing the release of DNA from damaged cells. Similarly, after massive PE, patients have widespread ischemic tissue damage derived from impaired lung function and abrupt systemic arterial hypotension. When appropriate treatment is started in these patients, the sudden return of oxygen at the onset of reperfusion with restoration of mitochondrial respiration will increase mitochondrial ROS formation to a level that exceeds the antioxidant capacity of the cells [33], causing mitochondria membrane rupture. Thus, it is likely that plasma mt-DNA will be a good new marker of the intensity of cell damage associated with ischemia and reperfusion injury. mt-DNA has been found to be a good early prognostic marker in out-of-hospital cardiac-arrest patients [23]. The current study demonstrates that plasma mt-DNA and n-DNA levels increase shortly after submassive or massive PE, and this elevation can be related to clinical severity and hospital mortality. Elevated mt-DNA is a strong predictor of 15-day mortality in massive PE, and it has better prognostic accuracy than n-DNA. Therefore, in contrast to previous reports testing simultaneously mt-DNA and n-DNA in different conditions [20-22], our data indicate that measurement of both markers is not necessary to increase the prognostic value.

Elevated plasma Tn-I and H-FABP levels are associated with RV dysfunction and have demonstrated significant prognostic value for risk stratifying in patients with normotensive PE [34,35]. However, their usefulness in the setting of massive PE remains unknown. In the present study, we found a significantly higher plasma concentration of H-FABP in nonsurviving than in surviving patients, but, even so, this marker was not so good a predictor of mortality as was plasma mt-DNA. A plausible

Table 3 ROC curves comparing the discriminant power of mt-DNA, H-FBAP, n-DNA and Tn-I to predict 15-day mortality in massive PE.

Test	Cutoff	AUC (95% CI)	Sens. (95% CI)	Spec (95% CI)	PPV (%)	NPV (%)	+LR	-LR	P value
mt-DNA	3380 GE/ml	0.89 (0.78-0.99)	94.4 (82.0-95.6)	68.4 (64.1-87.5)	73.9	92.9	17.6	0.08	<0.001
H-FBAP	6.8 ng/ml	0.76 (0.69-0.93)	88.9 (78.3-93.1)	85.7 (76.8-91.8)	69.5	85.7	6.2	0.13	<0.001
n-DNA	3625 GE/ml	0.73 (0.58-0.91)	77.8 (64.1-85.5)	57.9 (48.2-71.4)	63.6	73.3	5.03	0.38	<0.05
Tn-I	0.020 µg/ml	0.59 (0.41-0.79)	66.7 (51.3-78.0)	47.4 (35.2-60.1)	54.5	60.0	0.75	0.70	NS

explanation is that mt-DNA as a nonspecific global marker of cell death might better reflect the degree of widespread ischemic tissue damage that occurred in massive PE.

Our study showed that the basal lactate concentrations were significantly higher in hospital nonsurvivors than in survivors. Hyperlactatemia in critically ill patients may be attributed to anaerobic glycolysis resulting from inadequate tissue oxygenation, or it may be mediated by inflammation [36]. Excessive lactate production in our patients with acute PE is probably driven by two mechanisms, ischemia-reperfusion injury and the systemic inflammatory response, which both cause severe cell damage. The significant correlation between lactate concentrations and both mt-DNA and n-DNA observed in this study could be a direct consequence of the hypoxia-induced apoptosis and systemic inflammation.

This study provides some evidence regarding the origin of plasma nucleic acids from apoptotic cell death. Apoptosis is generated mainly by the Fas system. Fas (CD95) is a transmembrane protein that transduces a cell-death signal to the cytoplasm on its cross-linking with the Fas ligand (FasL). Hypoxia-induced cell death is known to occur

mainly via the mitochondrial (intrinsic) pathway of apoptosis [37], which could explain the stronger relation we found between sFas and mt-DNA. Our results are in line with the findings of histologic analysis of RV muscle from patients with fatal PE that shows accumulation of monocytes/macrophages in the RV, but without histologic evidence of cell necrosis [38]. Also, our findings are in keeping with recent data showing a high plasma cell-free nuclear DNA concentration and apoptotic DNA fragmentation in patients with bacteremia [39]. Further investigation is needed on the association of circulating markers of apoptosis, plasma mt-DNA concentration, and outcome in critical illness, particularly in massive PE.


Some methodologic limitations have to be considered in this study. First, the levels of the plasma nucleic acids may be influenced by age and underlying diseases. However, because no differences in age, predisposing factors, or comorbidities were found in survivors and nonsurvivors, it is likely that differences in plasma mt-DNA and n-DNA levels reflect the acute event of massive PE rather than chronic illness.

Second, excessive accumulation of DNA in plasma may be partly due to a decrease in clearance efficiency. We found that serum urea or creatinine concentrations were not independently associated with plasma mt-DNA and n-DNA concentrations, and this is consistent with data from experimental studies suggesting that renal clearance is not the main mechanism of removal for nucleic acids from the circulation [41-43]. However, further investigations are required to understand the dynamics of plasma DNA removal in patients with impaired renal and hepatic function.

Third, some potential confounders, such as patient management in the emergency department and intensive care unit, are difficult to control.

Fourth, we studied plasma levels only in the emergency department and did not measure levels serially, so we cannot assess the variation of nucleic acid levels in the intensive care unit or over time.

Fifth, our study design allows us to evaluate only associations, and not causes. Opposing these limitations, the



strengths of this study lie, first, in the prospective design that includes a clearly defined group of patients with massive and submassive PE. Second, we made a complete recording of predisposing risk factors, clinical and laboratory covariates, and cardiac biomarkers of severity, particularly H-FABP, against which plasma mitochondrial and nuclear DNA may be compared.

Third, it explores the potential association of apoptosis and soluble apoptotic signaling molecules with circulating nucleic acids.

Conclusions

This study first demonstrates that plasma levels of mt-DNA and n-DNA, and those of H-FABP and Tn-I, were significantly higher in patients with massive PE compared with those with submassive PE. Significantly higher values of all of them were observed in nonsurviving patients with massive PE than in those who survived. For the prediction of hospital mortality, plasma mt-DNA and H-FABP showed better discriminative power than did n-DNA. The significant association we found between plasma concentrations of both nucleic acids and the indirect marker of apoptosis, sFas, suggests that hypoxia activation of apoptosis may be the main source of plasmatic nucleic acids in PE. Further studies should analyze the relevance of plasma mt-DNA and H-FABP in rapidly identifying patients with massive PE embolism at the highest risk of mortality who may benefit from catheter-directed therapies if they are unable to receive thrombolytics.

Key messages

- Plasma mt-DNA and n-DNA concentrations are sensitive global indicator of 15-day mortality in patients arriving at the emergency department with massive PE.
- Plasma mitochondrial DNA concentration in the emergency department was 2 times higher in hospital nonsurvivors than in surviving patients.
- Plasma mt-DNA concentration is more powerful predictor than H-FABP or n-DNA on admission.
- Both plasma mt-DNA and H-FABP concentrations are strong independent early predictors for hospital mortality, whereas the plasma nuclear DNA seems to have a lower relevance.
- The observed significant association of circulating apoptosis markers sFas with plasma mitochondrial DNA could reflect the anoxia activation of the mitochondrial pathway of apoptosis.

Additional material

Additional file 1: METHODS: A. Echocardiography: Transthoracic echocardiography confirmed the presence of RV dysfunction in each case by any of the following parameters: a) RV/LV >0.6 with RV free wall hypokinesia; b) systolic flattening of the

interventricular septum; c) elevated tricuspid valve pressure gradient exceeding 30 mm Hg with a shortened acceleration time of pulmonary ejection below 80 m/s in the absence of RV hypertrophy. **B. Normal values and analytical detection limits of the assays:** The normal cutoff value for TnI is 0.08 ng/mL, and 125 pg/ml for NT-proBNP in patients <75 years old or < 450 pg/ml in patients ≥75 years old. The normal cutoff value for H-FABP is <1.6 ng/ml, with a detection limit of 102 pg/ml. The detection limit of markers involved in Fas-related apoptosis, human soluble Fas (sFas) and soluble Fas ligand (sFasL) were 20 pg/ml, with a detection limit of 2 pg/ml.

Additional file 2: Table S1. Comparison of factors between patients who receive and did not received thrombolysis

Abbreviations

AUC: area under the curve; BNP: brain natriuretic peptide; H-FABP: heart-type fatty acid-binding protein; mt-DNA: mitochondrial DNA; n-DNA: nuclear DNA; ROC: receiver operating curve; RV: right ventricle. sFas: soluble form of Fas molecule; sFasL: soluble form of Fas ligand molecule; Tn-I: troponin I.

Authors' contributions

FA, MCM, EC, RC, and CFC contributed to acquisition of the data; FA, JR, FGR, ELC, and CM participated in its design, coordination, and statistical analysis; RC and CM performed the molecular analysis; FA, FGR, ELC, and CM drafted the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

We thank Carolina Martin, Jose Luis Cedillo, and Gema Atienza for excellent technical assistance, and Rosario Madero for statistical analysis. This work was supported partially by grants from Plan Nacional I+D+I (SAF 2008-05347 and SAF2011-23575) and from Fundación Mutua Madrileña de Investigación Biomédica (2008 and 2011) to Francisco Arnalich and Carmen Montiel.

Author details

¹Department of Internal Medicine and Emergency Medicine Service, Hospital Universitario La Paz. IdiPAZ. Paseo de la Castellana 261.28046 Madrid, Spain.

²Department of Pharmacology and Therapeutics, Facultad de Medicina Universidad Autónoma de Madrid. IdiPAZ. Arzobispo Morcillo, 4. 28029 Madrid, Spain. ³Clinical Biochemistry Service, Hospital Universitario La Paz. IdiPAZ. Paseo de la Castellana 261.28046 Madrid, Spain. ⁴Biomedical Research Institute "Alberto Sols," Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid. IdiPAZ. Arturo Duperier, 4. 28029 Madrid, Spain. ⁵Preventive Medicine Service. ⁶Research Unit, Hospital Universitario La Paz. IdiPAZ. Paseo de la Castellana 261.28046 Madrid, Spain.

Received: 21 December 2012 Revised: 16 March 2013

Accepted: 24 May 2013 Published: 24 May 2013

References

1. Konstantinides S: **Clinical practice: acute pulmonary embolism.** *N Engl J Med* 2008, **359**:2804-2813.
2. Kucher N, Rossi E, De Rosa M, Goldhaber S: **Massive pulmonary embolism.** *Circulation* 2006, **113**:577-582.
3. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP: **Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).** *Eur Heart J* 2008, **29**:2276-2315.
4. Jaff MR, McMurry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK: **Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.** *Circulation* 2011, **123**:1788-1830.

5. ten Wolde M, Sohne M, Quak E, Mac Gillavry MR, Buller HR: **Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.** *Arch Intern Med* 2004, **164**:1685-1689.
6. Giannitsis E, Katus HA: **Risk stratification in pulmonary embolism based on biomarkers and echocardiography.** *Circulation* 2005, **112**:1520-1521.
7. Jiménez D, Aujesky D, Moores L, Gómez V, Martí D, Briongos S, Monreal M, Barrios V, Konstantinides S, Yusen RD: **Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism.** *Thorax* 2011, **66**:75-81.
8. van der Vaart M, Pretorius PJ: **Circulating DNA: its origin and fluctuation.** *Ann N Y Acad Sci* 2008, **1137**:18-26.
9. Peters DL, Pretorius PJ: **Origin, translocation and destination of extracellular occurring DNA: a new paradigm in genetic behavior.** *Clin Chim Acta* 2011, **412**:806-811.
10. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA: **Plasma DNA as a prognostic marker in trauma patients.** *Clin Chem* 2000, **46**:319-323.
11. Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, Lo YM: **Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke.** *Clin Chem* 2003, **49**:562-569.
12. Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT: **Elevated cell-free serum DNA detected in patients with myocardial infarction.** *Clin Chim Acta* 2003, **327**:95-101.
13. Chiu TW, Young R, Chan LY, Burd A, Lo DY: **Plasma cell-free DNA as an indicator of severity of injury in burn patients.** *Clin Chem Lab Med* 2006, **44**:13-17.
14. Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED: **Plasma DNA concentration as predictor of mortality and sepsis in critically ill patients.** *Crit Care* 2006, **10**:R60.
15. Saukkonen K, Lakkisto P, Varpula M, Varpula T, Voipio-Pulkki L-M, Pettilä V, Pulkki K: **Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care patients.** *Intensive Care Med* 2007, **33**:1624-1627.
16. Saukkonen K, Lakkisto P, Pettilä V, Varpula M, Karlsson S, Ruokonen E, Pulkki K: **Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock.** *Clin Chem* 2008, **54**:1000-1007.
17. Arnalich F, Maldifassi MC, Ciria E, Quesada A, Codoceo R, Herruzo R, Garcia-Cerrada C, Montoya F, Vazquez JJ, López-Collazo E, Montiel C: **Usefulness of cell-free plasma DNA to diagnose and predict mortality in patients with suspected acute mesenteric ischemia.** *Clin Chim Acta* 2010, **411**:1269-1274.
18. Arnalich F, Menéndez M, Lagos V, Ciria E, Quesada A, Codoceo R, Vazquez JJ, López-Collazo E, Montiel C: **Prognostic value of cell-free plasma DNA in patients with cardiac arrest outside the hospital: an observational cohort study.** *Crit Care* 2010, **14**:R47.
19. Huang CH, Tsai MS, Hsu CY, Chen HW, Wang TD, Chang WT, Ma MH, Chien KL, Chen SC, Chen WJ: **Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients.** *Resuscitation* 2012, **83**:213-218.
20. Tsai NW, Lin TK, Chen SD, Chang WN, Wang HC, Yang TM, Lin YJ, Jan CR, Huang CR, Liou CW, Lu CH: **The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke.** *Clin Chim Acta* 2011, **412**:476-479.
21. Lu CH, Chang WN, Tsai NW, Chuang YC, Huang CR, Wang HC: **The value of serial plasma and mitochondrial DNA levels in adult community-acquired bacterial meningitis.** *Q J Med* 2010, **103**:169-175.
22. Kung CT, Hsiao SY, Tsai TC, Su CM, Chang WN, Huang CR, Wang HC, Lin WC, Chang HW, Lin YJ, Cheng BC, Su BY, Tsai NW, Lu CH: **Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room.** *J Translation Med* 2012, **10**:130.
23. Arnalich F, Codoceo R, Lopez-Collazo E, Montiel C: **Circulating cell-free mitochondrial DNA: a better early prognostic marker in patients with out-of-hospital cardiac arrest.** *Resuscitation* 2012, **83**:e162-e163.
24. Goldhaber SZ, Hennekens CH, Markisz JA, McNeil BJ, Glynn MA, Bettman MA, Schur PH: **Low sensitivity of plasma DNA in screening for pulmonary embolism.** *Annu Rev Respir Dis* 1982, **126**:360-361.
25. Vargo JS, Becker DM, Philbrick JT, Schoonover FW, Davis JS: **Plasma DNA: a simple, rapid test for aiding the diagnosis of pulmonary embolism.** *Chest* 1990, **97**:63-68.
26. Green DR, Kroemer G: **The pathophysiology of mitochondrial cell death.** *Science* 2004, **305**:626-662.
27. aujesky D, Obrosky DS, Stone RA, auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ: **Derivation and validation of a prognostic model for pulmonary embolism.** *Am J Respir Crit Care Med* 2005, **172**:1041-1046.
28. de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, Renart J, Atienza G, Serantes R, Cruces J, Sánchez-Pacheco A, Andrés-Mateos E, Montiel C: **Function of partially duplicated human $\alpha 7$ nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response.** *J Biol Chem* 2011, **286**:594-606.
29. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, Wainscoat JS, Johnson PJ, Chang AM, Hjelm NM: **Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis.** *Am J Hum Genet* 1998, **62**:768-775.
30. Chiu RW, Chan LY, Lam NY, Tsui NB, Ng EK, Rainer TH, Lo YM: **Quantitative analysis of circulating mitochondrial DNA in plasma.** *Clin Chem* 2003, **49**:719-726.
31. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: **Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.** *Ann Intern Med* 2006, **145**:247-254.
32. DeLong ER, DeLong DM, Clarke-Pearson DL: **Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.** *Biometrics* 1988, **44**:837-845.
33. Yellow DM, Hausenloy DJ: **Myocardial reperfusion injury.** *N Engl J Med* 2007, **357**:1121-1135.
34. Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedemann B, Stolte D, Elmer G, Barthel P, Strasser RH: **Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk.** *Am Heart J* 2010, **160**:294-300.
35. Dellas C, Puls M, Lankeit M, Schäfer K, Cuny M, Berner M, Hasenfuss G, Konstantinides S: **Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism.** *J Am Coll Cardiol* 2010, **55**:2150-2157.
36. Mikkelsen ME, Mitiades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, Bellamy SL, Christie JD: **Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock.** *Crit Care Med* 2009, **37**:1670-1677.
37. Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman KG: **Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis.** *Cell Death Differ* 2007, **14**:411-421.
38. Iwadate K, Doi M, Tanno K, Katsumura S, Ito H, Sato K, Yonemura I, Ito Y: **Right ventricular damage due to pulmonary: examination of the number of infiltrating macrophages.** *Forensic Sci Int* 2003, **134**:147-153.
39. Huttunen R, Kuperinen T, Jylhäva J, Aittoniemi J, Vuento R, Huhtala H, Laine J, Syrjänen J, Hurme M: **Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation: a prospective cohort study.** *PLoS One* 2011, **6**:e21700.
40. Fournie GJ, Martres F, Porrat JP, Alary C, Rumeau M: **Plasma DNA as cell death marker in elderly patients.** *Gerontology* 1993, **39**:215-221.
41. Gauntier VJ, Tyler LN, Mannik M: **Blood clearance kinetics and liver uptake of mononucleosomes in mice.** *J Immunol* 1996, **156**:1151-1156.
42. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A: **Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism.** *Clin Chem* 2000, **46**:1078-1084.
43. Korabecna M, Opatrna S, Jan Wirth J, Rulcova K, Eiselt J, Seřrna F, Horinek A: **Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease.** *Ann N Y Acad Sci* 2008, **1137**:296-301.

doi:10.1186/cc12735

Cite this article as: Arnalich et al.: Plasma levels of mitochondrial and nuclear DNA in patients with massive pulmonary embolism in the emergency department: a prospective cohort study. *Critical Care* 2013 **17**:R90.